Respiratory Syncytial Virus (RSV) hospitalises thousands of children each year, yet effective treatments remain unavailable. This research investigates a critical protein–protein interaction that enables RSV infection. By identifying and disrupting key molecular binding sites using AI, the work aims to support the development of targeted antiviral therapies for severe RSV.

This research tests whether positive, therapy-induced epigenetic changes can be inherited. Using mice with genetic eye disease, the team applies a successful treatment, checks for vision improvement, examines resulting DNA chemical marks, and studies whether offspring inherit these beneficial modifications. Findings could reshape our understanding of therapy and generational health impact.